{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Non-Small+Cell+Neoplasm+of+Lung&page=27", "query": { "condition": "Squamous Non-Small Cell Neoplasm of Lung", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 741, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Non-Small+Cell+Neoplasm+of+Lung&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Non-Small+Cell+Neoplasm+of+Lung&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T14:38:19.604Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Small Cell and Non-small Cell Lung Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Other Specified Sites of Skin", "Malignant Melanoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Renal Cell", "Breast Neoplasms", "Urinary Bladder Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Colorectal Neoplasms", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "SGN-2FF", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-02-23", "completion_date": "2019-06-24", "has_results": false, "last_update_posted_date": "2019-07-19", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952989" }, { "nct_id": "NCT04173338", "title": "Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Non-squamous Non-small-cell Lung Cancer", "Urothelial Carcinoma", "Malignant Mesothelioma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-01-23", "completion_date": "2022-03-28", "has_results": false, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04173338" }, { "nct_id": "NCT01727076", "title": "Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Skin Carcinoma", "Stage III Renal Cell Cancer", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Recombinant Human Interleukin-15", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 20, "start_date": "2013-02-15", "completion_date": "2016-06-30", "has_results": false, "last_update_posted_date": "2017-09-15", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 5, "location_summary": "Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727076" }, { "nct_id": "NCT01868022", "title": "Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3052230", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2013-10-09", "completion_date": "2017-10-24", "has_results": true, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 10, "location_summary": "Duarte, California • Sacramento, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01868022" }, { "nct_id": "NCT07005102", "title": "A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer", "c-MET" ], "interventions": [ { "name": "Standard of Care", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Osimertinib (Osi)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 854, "start_date": "2025-08-03", "completion_date": "2036-11", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 18, "location_summary": "Chandler, Arizona • Duarte, California • Irvine, California + 15 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07005102" }, { "nct_id": "NCT07489066", "title": "Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Non-Small-Cell Lung", "Lung Cancer (NSCLC)", "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung (NSCLC)", "Lung Disease", "Non-Small Cell Lung Cancer", "Non-small Cell Lung Cancer, Non-squamous", "Non-small Cell Lung Cancer, Squamous" ], "interventions": [ { "name": "PF-08634404", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Regimen 1", "type": "DRUG" }, { "name": "Chemotherapy Regimen 2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-06-30", "completion_date": "2031-07-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 15, "location_summary": "Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07489066" }, { "nct_id": "NCT01726296", "title": "Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adenocarcinoma of the Lung", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Squamous Cell Lung Cancer", "Stage I Colon Cancer", "Stage I Rectal Cancer", "Stage IA Non-small Cell Lung Cancer", "Stage IB Non-small Cell Lung Cancer", "Stage IIA Colon Cancer", "Stage IIA Non-small Cell Lung Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Non-small Cell Lung Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1440, "start_date": "2013-01", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2017-04-06", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726296" }, { "nct_id": "NCT07555210", "title": "Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer (Triple Negative Breast Cancer (TNBC))", "Renal Cell Carcinoma (Kidney Cancer)", "Melanoma (Skin Cancer)", "Non-Small Cell Lung Cancer", "MSI-H/dMMR Rectal Cancer", "Squamous Cell Carcinoma Mouth", "Invasive Mammary Carcinoma", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Dual-Energy X-ray Absorptiometry (DXA)", "type": "DEVICE" }, { "name": "High Resolution peripheral Quantitative Computed Tomography (HRpQCT)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Jessica Mezzanotte Sharpe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-08-25", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07555210" }, { "nct_id": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1310", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2023-08-17", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-16T14:38:19.604Z", "location_count": 15, "location_summary": "Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785741" } ] }